VYNE Therapeutics Inc. (NASDAQ:VYNE) Short Interest Update

VYNE Therapeutics Inc. (NASDAQ:VYNE) was the target of a significant decrease in short interest in the month of November. As of November 30th, there was short interest totalling 64,300 shares, a decrease of 37.1% from the November 15th total of 102,200 shares. Based on an average trading volume of 81,800 shares, the days-to-cover ratio is currently 0.8 days. Approximately 0.5% of the company’s shares are short sold.

VYNE Therapeutics Trading Up 6.7 %

Shares of VYNE opened at $2.56 on Friday. The firm has a fifty day moving average price of $2.63 and a 200-day moving average price of $2.20. The firm has a market capitalization of $37.76 million, a P/E ratio of -2.98 and a beta of 1.37. VYNE Therapeutics has a 12-month low of $1.57 and a 12-month high of $3.43.

Institutional Investors Weigh In On VYNE Therapeutics

A hedge fund recently bought a new stake in VYNE Therapeutics stock. Lynx1 Capital Management LP purchased a new stake in shares of VYNE Therapeutics Inc. (NASDAQ:VYNE) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 16,194 shares of the company’s stock, valued at approximately $32,000. VYNE Therapeutics accounts for about 0.0% of Lynx1 Capital Management LP’s holdings, making the stock its 17th largest position. Lynx1 Capital Management LP owned about 0.11% of VYNE Therapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 83.78% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on VYNE shares. BTIG Research assumed coverage on shares of VYNE Therapeutics in a research note on Monday, November 18th. They set a “buy” rating and a $8.00 price target for the company. HC Wainwright restated a “buy” rating and set a $5.75 target price on shares of VYNE Therapeutics in a research report on Friday, November 8th.

VYNE Therapeutics Company Profile

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.